Stage IIIB Breast Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01959490Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast CancerBasic Science
NCT00119262Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerTreatment